Showing results (1551-1560 of 6,509) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|October 9, 2024
Optimizing cancer classification: a hybrid RDO-XGBoost approach for feature selection and predictive insightsAbrar Yaqoob, Navneet Kumar Verma, Rabia Musheer Aziz, et al.Cancer Immunology, Immunotherapy : CII|October 9, 2024
Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancerHye In Kim, Won Gu Kim, Mijin Kim, et al.Cancer Immunology, Immunotherapy : CII|February 23, 2026
Defining alteration in bone marrow mesenchymal stem cells (MSC) from acute myeloid leukemia and exploring cultured MSC-conditioned media as a novel anti-leukemia therapy agentManasi Nagare, Monalisa Sahoo, Manju Sengar, et al.Cancer Immunology, Immunotherapy : CII|November 13, 2024
"Tumor immunology meets oncology" (TIMO), 18 April-20 April 2024, in Brandenburg an der Havel, GermanyBarbara SeligerCancer Immunology, Immunotherapy : CII|November 2, 2024
Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposalXinya Li, Zaiwei Song, Yixuan Chen, et al.Cancer Immunology, Immunotherapy : CII|November 2, 2024
Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cellsMarat Khaliulin, Aygul Valiullina, Alexey Petukhov, et al.Cancer Immunology, Immunotherapy : CII|November 2, 2024
Ly6E on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune exclusionLan Hailin, Chen Yiting, Wu Yue, et al.Cancer Immunology, Immunotherapy : CII|November 2, 2024
Phenotypic insights into genetic risk factors for immune-related adverse events in cancer immunotherapyHaochuan Ma, Dili Song, Haibo Zhang, et al.Cancer Immunology, Immunotherapy : CII|November 2, 2024
Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancerYuichi Ozawa, Yasuhiro Koh, Ryota Shibaki, et al.Cancer Immunology, Immunotherapy : CII|May 7, 2026
αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinomaKwanpirom Suwanchiwasiri, Chalermchai Somboonpatarakun, Nan Chaiyariti, et al.Pageof 651